Medite Cancer Diagnostics (MDIT) Stock Price
Medite Cancer Diagnostics Price
Revenue has compounded at 11.0% per year over the past 18 years to 6.81 M USD. Medite Cancer Diagnostics's net margin stands at -100.0%, down from 225.0% several years earlier.
Medite Cancer Diagnostics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Medite Cancer Diagnostics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Medite Cancer Diagnostics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Medite Cancer Diagnostics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Medite Cancer Diagnostics Price |
|---|---|
| 8/19/2026 | 0.00 USD |
| 8/18/2026 | 0.00 USD |
| 8/17/2026 | 0.00 USD |
| 8/14/2026 | 0.00 USD |
| 8/13/2026 | 0.00 USD |
| 8/12/2026 | 0.00 USD |
| 8/11/2026 | 0.00 USD |
| 8/10/2026 | 0.00 USD |
| 8/7/2026 | 0.00 USD |
| 8/6/2026 | 0.00 USD |
| 8/5/2026 | 0.00 USD |
| 8/4/2026 | 0.00 USD |
| 8/3/2026 | 0.00 USD |
| 7/30/2026 | 0.00 USD |
| 7/29/2026 | 0.00 USD |
| 7/28/2026 | 0.00 USD |
| 7/27/2026 | 0.00 USD |
| 7/24/2026 | 0.00 USD |
| 7/23/2026 | 0.00 USD |
| 7/22/2026 | 0.00 USD |
| 7/21/2026 | 0.00 USD |
| 7/20/2026 | 0.00 USD |
| 7/17/2026 | 0.00 USD |
| 7/16/2026 | 0.00 USD |
| 7/15/2026 | 0.00 USD |
| 7/14/2026 | 0.00 USD |
| 7/13/2026 | 0.00 USD |
| 7/10/2026 | 0.00 USD |
| 7/9/2026 | 0.00 USD |
| 7/8/2026 | 0.00 USD |
| 7/7/2026 | 0.00 USD |
| 7/6/2026 | 0.00 USD |
| 7/2/2026 | 0.00 USD |
| 7/1/2026 | 0.00 USD |
| 6/30/2026 | 0.00 USD |
| 6/29/2026 | 0.00 USD |
| 6/26/2026 | 0.00 USD |
| 6/25/2026 | 0.00 USD |
| 6/24/2026 | 0.00 USD |
| 6/23/2026 | 0.00 USD |
| 6/22/2026 | 0.00 USD |
| 6/18/2026 | 0.00 USD |
| 6/17/2026 | 0.00 USD |
| 6/16/2026 | 0.00 USD |
| 6/15/2026 | 0.00 USD |
| 6/12/2026 | 0.00 USD |
| 6/11/2026 | 0.00 USD |
| 6/10/2026 | 0.00 USD |
| 6/9/2026 | 0.00 USD |
| 6/8/2026 | 0.00 USD |
| 6/5/2026 | 0.00 USD |
| 6/4/2026 | 0.00 USD |
| 6/3/2026 | 0.00 USD |
| 6/2/2026 | 0.00 USD |
| 6/1/2026 | 0.00 USD |
| 5/29/2026 | 0.00 USD |
| 5/28/2026 | 0.00 USD |
| 5/27/2026 | 0.00 USD |
| 5/26/2026 | 0.00 USD |
| 5/22/2026 | 0.00 USD |
| 5/21/2026 | 0.00 USD |
| 5/20/2026 | 0.00 USD |
| 5/19/2026 | 0.00 USD |
| 5/18/2026 | 0.00 USD |
| 5/15/2026 | 0.00 USD |
| 5/14/2026 | 0.00 USD |
| 5/13/2026 | 0.00 USD |
| 5/12/2026 | 0.00 USD |
| 5/11/2026 | 0.00 USD |
| 5/8/2026 | 0.00 USD |
| 5/7/2026 | 0.00 USD |
| 5/6/2026 | 0.00 USD |
| 5/5/2026 | 0.00 USD |
| 5/4/2026 | 0.00 USD |
| 5/1/2026 | 0.00 USD |
| 4/30/2026 | 0.00 USD |
| 4/29/2026 | 0.00 USD |
| 4/28/2026 | 0.00 USD |
| 4/27/2026 | 0.00 USD |
| 4/24/2026 | 0.00 USD |
| 4/23/2026 | 0.00 USD |
| 4/22/2026 | 0.00 USD |
| 4/21/2026 | 0.00 USD |
| 4/20/2026 | 0.00 USD |
| 4/17/2026 | 0.00 USD |
| 4/16/2026 | 0.00 USD |
| 4/15/2026 | 0.00 USD |
| 4/14/2026 | 0.00 USD |
| 4/13/2026 | 0.00 USD |
| 4/10/2026 | 0.00 USD |
| 4/9/2026 | 0.00 USD |
| 4/8/2026 | 0.00 USD |
| 1/27/2026 | 0.00 USD |
| 1/9/2026 | 0.00 USD |
| 9/24/2025 | 0.00 USD |
| 8/28/2025 | 0.01 USD |
Medite Cancer Diagnostics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Medite Cancer Diagnostics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.00 | – | – | – | – | – | – | – | – | – | – | – | 10.00 | 9.00 | 9.00 | 6.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -10.00 | – | -33.33 |
| 300.00 | – | – | – | – | – | – | – | – | – | – | – | 30.00 | 33.33 | 33.33 | 50.00 |
| 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| -10.00 | -6.00 | -5.00 | -1.00 | -5.00 | -8.00 | -6.00 | -3.00 | -1.00 | -2.00 | -1.00 | – | – | – | -1.00 | -6.00 |
| -1,000.00 | – | – | – | – | – | – | – | – | – | – | – | – | – | -11.11 | -100.00 |
| -13.00 | -11.00 | -14.00 | -4.00 | -7.00 | -8.00 | -6.00 | -3.00 | -2.00 | -3.00 | -1.00 | – | – | – | -2.00 | -6.00 |
| -31.58 | -15.38 | 27.27 | -71.43 | 75.00 | 14.29 | -25.00 | -50.00 | -33.33 | 50.00 | -66.67 | – | – | – | – | 200.00 |
| 0.03 | 0.04 | 0.08 | 0.11 | 0.24 | 0.34 | 0.40 | 0.42 | 0.46 | 0.58 | 0.72 | 29.18 | 41.32 | 2.06 | 24.25 | 29.18 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Medite Cancer Diagnostics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Medite Cancer Diagnostics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Medite Cancer Diagnostics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Medite Cancer Diagnostics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Medite Cancer Diagnostics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Medite Cancer Diagnostics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Medite Cancer Diagnostics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Medite Cancer Diagnostics business model & stock analysis
Medite Cancer Diagnostics SWOT Analysis
Strengths
Medite Cancer Diagnostics Inc has several strengths:
- Advanced technology and innovative products
- Strong research and development capabilities
- Established partnerships with healthcare institutions
- Expert team of scientists and medical professionals
- Solid financial position and steady revenue growth
Weaknesses
There are a few weaknesses that Medite Cancer Diagnostics Inc should address:
- Limited global market presence
- Dependency on a few key suppliers
- Relatively small-scale operations compared to competitors
- High research and development costs affecting profitability
- Challenges in expanding into emerging markets
Opportunities
Medite Cancer Diagnostics Inc can take advantage of the following opportunities:
- Increasing demand for cancer diagnostics globally
- Emerging markets offering growth potential
- Collaboration opportunities with academic institutions
- Technological advancements in the healthcare industry
- Expanding product portfolio to cater to different cancer types
Threats
Medite Cancer Diagnostics Inc should be cautious of the following threats:
- Intense competition from larger and well-established companies
- Stringent regulatory requirements and compliance
- Potential disruptions in the supply chain
- Rapidly changing technological landscape in the industry
- Economic volatility impacting healthcare spending
Medite Cancer Diagnostics Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Medite Cancer Diagnostics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Medite Cancer Diagnostics historical P/E ratio, EBIT multiple, and P/S ratio
Medite Cancer Diagnostics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Medite Cancer Diagnostics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Medite Cancer Diagnostics stock splits
Medite Cancer Diagnostics shareholder structure
| % | Name |
|---|---|
0.00011% | |
0.00000% |
Medite Cancer Diagnostics Beneficial Ownership Filings (SEC 13D/G)
Medite Cancer Diagnostics Executives and Management Board
7 members · avg. age 59 · 14 % women
Mrs. Michaela Ott (55)
Chief Operating Officer · since 2014
149,784.00 USD
Management
Mr. Jeff Rencher (53)
Chief Marketing and Business Development Officer
Board of Directors
Mr. William Lewis (45)
Independent Chairman of the Board
Dr. John Abeles (75)
Independent Director
Mr. Alexander Milley (69)
Independent Director
Mr. Gregory Fortunoff (51)
Director
Mr. Joel Kanter (62)
Independent Director
Frequently asked questions about Medite Cancer Diagnostics
Medite Cancer Diagnostics Inc. operates as a medical technology company focused on the development, manufacture, and marketing of innovative molecular biomarker diagnostic solutions for cutting-edge cancer testing. The business model of Medite Cancer Diagnostics Inc. primarily revolves around enhancing cancer diagnosis through the provision of a wide range of advanced diagnostic products and services. By employing unique molecular biomarker technology, Medite Cancer Diagnostics Inc. aims to offer accurate and personalized cancer testing solutions to healthcare professionals and laboratories worldwide. Through continuous research and development, Medite Cancer Diagnostics Inc. strives to contribute to improved patient outcomes and revolutionize cancer diagnostics in the medical industry.
Medite Cancer Diagnostics Inc is primarily active in the healthcare industry. As a leading provider of innovative cancer diagnostic solutions, Medite Cancer Diagnostics Inc offers a wide range of products and services to assist medical professionals in accurately diagnosing and monitoring various types of cancers. With its advanced technologies and expertise, the company aims to enhance precision and efficacy in cancer detection, contributing to improved patient outcomes. Medite Cancer Diagnostics Inc remains committed to advancing the field of cancer diagnostics and making a positive impact on the lives of individuals affected by this disease.
Some of the main competitors of Medite Cancer Diagnostics Inc in the market include Hologic Inc, Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific.
Medite Cancer Diagnostics Inc is a renowned company focused on providing innovative solutions for cancer diagnosis. With a rich history spanning several years, the company has established a strong reputation for its cutting-edge technologies in histopathology. Medite Cancer Diagnostics Inc has developed a wide range of high-quality instruments and reagents used in the analysis of cancer tissue samples. Their products are designed to improve accuracy, efficiency, and standardization in pathology laboratories, ultimately leading to better patient outcomes. As a global leader in cancer diagnostics, Medite Cancer Diagnostics Inc continually strives to revolutionize the field by delivering advanced solutions and driving progress in cancer research and treatment.
Some significant milestones achieved by Medite Cancer Diagnostics Inc include the development and launch of cutting-edge diagnostic products to aid in cancer detection and diagnosis. The company has also expanded its global presence and established partnerships with renowned medical institutions. Medite Cancer Diagnostics Inc has continuously conducted research and development to enhance their product portfolio, ensuring innovative and reliable solutions for cancer diagnosis. Moreover, the company has received multiple regulatory approvals, further validating the quality and effectiveness of their products. These milestones highlight Medite Cancer Diagnostics Inc's commitment to advancing cancer diagnostics and improving patient outcomes.
Medite Cancer Diagnostics Inc is primarily present in several countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered. Additionally, Medite Cancer Diagnostics Inc has a strong foothold in Europe, with a focus on countries such as Germany, Italy, and France. The company also operates in Asia, particularly in countries like China and India. With its global reach, Medite Cancer Diagnostics Inc serves healthcare providers, laboratories, and research institutions across these regions, offering innovative diagnostic solutions for cancer detection and diagnosis.
Medite Cancer Diagnostics Inc represents a dedication to providing innovative and reliable products and solutions for cancer diagnostics. With a strong focus on enhancing patient care, the company values accuracy, quality, and efficiency in its offerings. Medite Cancer Diagnostics Inc is committed to advancing the field of cancer detection through advanced technology and research. The company's corporate philosophy revolves around improving the lives of patients by delivering timely and precise diagnostic tools, enabling early detection and personalized treatment. Medite Cancer Diagnostics Inc strives to foster strong partnerships with healthcare professionals and institutions, ensuring the highest standards of care and improving patient outcomes.
Converted at the current exchange rate, the Medite Cancer Diagnostics share trades at 0.00 EUR (0.00 USD).
The company Medite Cancer Diagnostics Inc. is a company based in Orlando, Florida, specializing in cancer diagnostics. The company aims to develop faster, more accurate, and cost-effective diagnostic tests to improve the treatment of cancer in early stages. The company focuses on developing products that assist doctors and laboratories in diagnosing cancer by improving the accuracy and reliability of the diagnosis. The company's business model consists of various divisions. On one hand, Medite Cancer Diagnostics offers a wide range of products for cancer diagnostics, which are used by laboratories and hospitals worldwide. On the other hand, the company provides services in the field of clinical laboratory services and supports medical facilities in implementing cancer diagnostic guidelines. Medite Cancer Diagnostics' product range includes a variety of tests and devices that can be used in cancer diagnostics. Among other things, the company offers devices for histology and cytology, which are used in the examination of tissue samples for diagnosing cancer. Furthermore, the company has developed tests that support the diagnosis of prostate cancer and colorectal cancer. Another important aspect of Medite Cancer Diagnostics' business model is the provision of clinical laboratory services. The company supports laboratories in implementing cancer diagnostic guidelines and ensuring optimal patient care. Medite Cancer Diagnostics offers services such as DNA analysis, specialized cell analysis technologies, and digital histology. The business model of Medite Cancer Diagnostics is supported by a strong focus on research and development. The company continuously invests in the development of new tests and technologies for cancer diagnostics, collaborating closely with academic institutions and other leading research facilities. This enables the company to quickly adapt to changing requirements in the healthcare market and respond to the needs of patients more effectively. Overall, Medite Cancer Diagnostics is now a leading provider of cancer diagnostics products and services. The company has achieved a strong market position by focusing on research, development, and innovation. The combination of a wide product range, high-quality services, extensive research, and dedicated employees has made the company an important player in the international market for cancer diagnostics.
The revenue cannot currently be calculated for Medite Cancer Diagnostics.
The profit cannot currently be calculated for Medite Cancer Diagnostics.
The P/E ratio cannot be calculated for Medite Cancer Diagnostics at the moment.
The P/S cannot be calculated for Medite Cancer Diagnostics currently.
The Eulerpool Quality Score for Medite Cancer Diagnostics is 2/10.
The ISIN of Medite Cancer Diagnostics is US58503D2009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Medite Cancer Diagnostics is A14QAX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Medite Cancer Diagnostics is MDIT. The ticker symbol is used to trade Medite Cancer Diagnostics shares on the stock exchange.
Medite Cancer Diagnostics paid dividends every year for the past 0 years.
Medite Cancer Diagnostics is assigned to the 'Health' sector.
The dividends of Medite Cancer Diagnostics are distributed in USD.
Medite Cancer Diagnostics stock
Medite Cancer Diagnostics Peer Group
Medite Cancer Diagnostics Ticker
Medite Cancer Diagnostics FIGI
All fundamentals and in-depth analysis of Medite Cancer Diagnostics
Our stock analysis for Medite Cancer Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medite Cancer Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.